Hikma intros dobutamine injection
Hikma is introducing dobutamine injection, in a 250 mg/20 ml vial. With this launch, Hikma’s growing U.S. portfolio of sterile injectable medicines now exceeds 150 products spanning a wide range of therapeutic areas and dosage forms.
Dobutamine Injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
“Our portfolio of more than 150 injectable medicines has expanded by more than 50% over the last three years, driven by customer needs, an expansion of our capabilities and product offerings, and the continued recognition of Hikma as a reliable, high-quality supplier of sterile injectable medicines,” said Riad Mishlawi, president of injectables at Hikma.
[Read more: Avalere analysis examines Medicare Part D’s plan tier placement of generics]
Mishlawi added, “As a top-three supplier of generic injectable medicines by volume in the United States, we are proud of the important role we play in the U.S. healthcare system. We are committed to further growing our portfolio and capabilities and continuing to supply essential medicines to U.S. hospitals, doctors and patients.”
Dobutamine injection had a market value of roughly $2 million in the 12 months ending April 2023, per IQVIA.
[Read more: Challenges continue, but generics companies see a bright future with biosimilars]
In addition to its growing U.S. portfolio, Hikma now markets approximately 30 sterile injectable medicines in Canada, with plans to launch up to 13 additional products this year. The company also has launched Hikma 503B, a new sterile compounding business focused on providing high-quality, ready-to-administer injectable medications that are customized to the specific needs of patients in the United States.